Kei Man (Jovi) Cheng

Ms. Cheng’s recent representative experience includes advising:

• The underwriters on the HK$1.014 billion initial public offering of shares on the Main Board of the Hong Kong Stock Exchange for JF Wealth, a leading online investment decision-making solution provider in China  
• Tianqi Lithium, a leading global lithium producer, on its HK$13.5 billion (US$1.7 billion) H share initial public offering on the Main Board of The Stock Exchange of Hong Kong Limited
• Zai Lab Limited in its US$766 million secondary listing and initial public offering in Hong Kong*
• Pop Mart International Group Limited in its HK$5.2 billion initial public offering in Hong Kong*
• Hangzhou Tigermed Consulting Co., Ltd. in its HK$10.7 billion initial public offering in Hong Kong*
• Antengene Corporation Limited in its HK$2.79 billion initial public offering in Hong Kong*
• Morgan Stanley Asia Limited, Huatai Financial Holdings (Hong Kong) Limited and J.P. Morgan Securities (Far East) Limited as the underwriters’ counsel in respect of the HK$4 billion initial public offering of RemeGen Co., Ltd. In Hong Kong*
• Ming Yuan Cloud Group Holdings Limited in its HK$6.2 billion initial public offering in Hong Kong*
• Venus Medtech (Hangzhou) Inc. in its placing of HK$1.2 billion new H shares in Hong Kong*

*Matter handled prior to joining Latham